Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 9, 2007, Pages 1103-1111

  Ranney, Melissa K ^a   Ahmed, Ikhlas S A ^a   Potts, Kelly R ^a   Craven, Rolf J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Apoptosis; Breast cancer; Calpain; Caspase; Clusterin; Doxorubicin; Histone deacetylase; PARP; Proteasome

Indexed keywords

BUTYRIC ACID; CAMPTOTHECIN; CLUSTERIN; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; PROTEASOME; VORINOSTAT;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL SURVIVAL; CHROMATIN STRUCTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME LOCALIZATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; TUMOR CELL;

APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CLUSTERIN; CYTOCHROMES C; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 34548173298     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2007.06.004     Document Type: Article

References (63)

1. Goodman L.S., Gilman A., Brunton L.L., Lazo J.S., and Parker K.L. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill Medical Pub. Division, New York
2. Pommier Y., Sordet O., Antony S., Hayward R.L., and Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23 (2004) 2934-2949
3. Dashwood R.H., Myzak M.C., and Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?. Carcinogenesis 27 (2006) 344-349
4. Roy C.C., Kien C.L., Bouthillier L., and Levy E. Short-chain fatty acids: ready for prime time?. Nutr. Clin. Pract. 21 (2006) 351-366
5. Dokmanovic M., and Marks P.A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem. 96 (2005) 293-304
6. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., and Munster P.N. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol. Cancer Ther. 4 (2005) 1993-2000
7. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., and Munster P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 65 (2005) 3815-3822
8. Bevins R.L., and Zimmer S.G. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 65 (2005) 6957-6966
9. Marchion D.C., Bicaku E., Daud A.I., Richon V., Sullivan D.M., and Munster P.N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J. Cell. Biochem. 92 (2004) 223-237
10. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63 (2003) 7291-7300
11. Joseph J., Mudduluru G., Antony S., Vashistha S., Ajitkumar P., and Somasundaram K. Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23 (2004) 6304-6315
12. Davie J.R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133 (2003) 2485S-2493S
13. Ogawa K., Yasumura S., Atarashi Y., Minemura M., Miyazaki T., Iwamoto M., Higuchi K., and Watanabe A. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J. Hepatol. 40 (2004) 278-284
14. Place R.F., Noonan E.J., and Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem. Pharmacol. 70 (2005) 394-406
15. Humphreys D.T., Carver J.A., Easterbrook-Smith S.B., and Wilson M.R. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 274 (1999) 6875-6881
16. Trougakos I.P., and Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell. Biol. 34 (2002) 1430-1448
17. Mallory J.C., Crudden G., Oliva A., Saunders C., Stromberg A., and Craven R.J. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol. Pharmacol. 68 (2005) 1747-1756
18. So A., Sinnemann S., Huntsman D., Fazli L., and Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol. Cancer Ther. 4 (2005) 1837-1849
19. Trougakos I.P., So A., Jansen B., Gleave M.E., and Gonos E.S. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64 (2004) 1834-1842
20. Miyake H., Hara I., Kamidono S., Gleave M.E., and Eto H. Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. Oncol. Rep. 10 (2003) 469-473
21. Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60 (2000) 2547-2554
22. Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., and Gleave M.E. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 3 (2001) 360-367
23. July L.V., Beraldi E., So A., Fazli L., Evans K., English J.C., and Gleave M.E. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3 (2004) 223-232
24. Chen X., Halberg R.B., Ehrhardt W.M., Torrealba J., and Dove W.F. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9530-9535
25. Redondo M., Villar E., Torres-Munoz J., Tellez T., Morell M., and Petito C.K. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157 (2000) 393-399
26. Xie D., Lau S.H., Sham J.S., Wu Q.L., Fang Y., Liang L.Z., Che L.H., Zeng Y.X., and Guan X.Y. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma. Cancer 103 (2005) 277-283
27. Lau S.H., Sham J.S., Xie D., Tzang C.H., Tang D., Ma N., Hu L., Wang Y., Wen J.M., Xiao G., Zhang W.M., Lau G.K., Yang M., and Guan X.Y. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25 (2006) 1242-1250
28. Saffer H., Wahed A., Rassidakis G.Z., and Medeiros L.J. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod. Pathol. 15 (2002) 1221-1226
29. Humphreys D., Hochgrebe T.T., Easterbrook-Smith S.B., Tenniswood M.P., and Wilson M.R. Effects of clusterin overexpression on TNFalpha- and TGFbeta-mediated death of L929 cells. Biochemistry 36 (1997) 15233-15243
30. Yang C.R., Leskov K., Hosley-Eberlein K., Criswell T., Pink J.J., Kinsella T.J., and Boothman D.A. Nuclear clusterin/XIP8, an X-ray-induced Ku70-binding protein that signals cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 5907-5912
31. Reddy K.B., Jin G., Karode M.C., Harmony J.A., and Howe P.H. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35 (1996) 6157-6163
32. Leskov K.S., Klokov D.Y., Li J., Kinsella T.J., and Boothman D.A. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278 (2003) 11590-11600
33. O'Sullivan J., Whyte L., Drake J., and Tenniswood M. Alterations in the post-translational modification and intracellular trafficking of clusterin in MCF-7 cells during apoptosis. Cell Death Differ. 10 (2003) 914-927
34. Zhang H., Kim J.K., Edwards C.A., Xu Z., Taichman R., and Wang C.Y. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 7 (2005) 909-915
35. Debure L., Vayssiere J.L., Rincheval V., Loison F., Le Drean Y., and Michel D. Intracellular clusterin causes juxtanuclear aggregate formation and mitochondrial alteration. J. Cell. Sci. 116 (2003) 3109-3121
36. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., and Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (2001) 727-730
37. Schafer Z.T., and Kornbluth S. The apoptosome: physiological, developmental, and pathological modes of regulation. Dev. Cell 10 (2006) 549-561
38. Fisher T.S., and Zakian V.A. Ku: a multifunctional protein involved in telomere maintenance. DNA Repair 4 (2005) 1215-1226
39. Cailleau R., Olive M., and Cruciger Q.V. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In vitro 14 (1978) 911-915
40. Hand R.A., and Craven R.J. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J. Cell. Biochem. 90 (2003) 534-547
41. Cance W.G., Craven R.J., and Liu E.T. Expression polymerase chain reaction: a sensitive method for analysis of gene expression in human tumours. Surg. Oncol. 1 (1992) 309-314
42. Gao M., Fan S., Goldberg I.D., Laterra J., Kitsis R.N., and Rosen E.M. Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J. Biol. Chem. 276 (2001) 47257-47265
43. Meng L., Mohan R., Kwok B.H., Elofsson M., Sin N., and Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10403-10408
44. Bo Kim K., Fonseca F.N., and Crews C.M. Development and characterization of proteasome inhibitors. Methods Enzymol. 399 (2005) 585-609
45. Chinnaiyan A.M., O'Rourke K., Tewari M., and Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81 (1995) 505-512
46. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., and Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270 (1995) 7795-7798
47. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., Altucci L., Nervi C., Minucci S., and Pelicci P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11 (2005) 71-76
48. Roos-Mattjus P., and Sistonen L. The ubiquitin-proteasome pathway. Ann. Med. 36 (2004) 285-295
49. Nakanishi C., and Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev., Cancer 5 (2005) 297-309
50. Scaltriti M., Santamaria A., Paciucci R., and Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 64 (2004) 6174-6182
51. Yin L., Laevsky G., and Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J. Biol. Chem. 276 (2001) 44641-44646
52. Boatright K.M., and Salvesen G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15 (2003) 725-731
53. Daly K., and Shirazi-Beechey S.P. Microarray analysis of butyrate regulated genes in colonic epithelial cells. DNA Cell Biol. 25 (2006) 49-62
54. Chopin V., Slomianny C., Hondermarck H., and Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp. Cell Res. 298 (2004) 560-573
55. Chopin V., Toillon R.A., Jouy N., and Le Bourhis X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br. J. Pharmacol. 135 (2002) 79-86
56. Tsubaki J., Choi W.K., Ingermann A.R., Twigg S.M., Kim H.S., Rosenfeld R.G., and Oh Y. Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells. J. Endocrinol. 169 (2001) 97-110
57. Liu Z.G., Hsu H., Goeddel D.V., and Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87 (1996) 565-576
58. Ting A.T., Pimentel-Muinos F.X., and Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 15 (1996) 6189-6196
59. Lund P., Weisshaupt K., Mikeska T., Jammas D., Chen X., Kuban R.J., Ungethum U., Krapfenbauer U., Herzel H.P., Schafer R., Walter J., and Sers C. Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation. Oncogene 25 (2006) 4890-4903
60. Leder A., and Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 5 (1975) 319-322
61. Abe M., and Kufe D.W. Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production. Breast Cancer Res. Treat. 4 (1984) 269-274
62. Biroccio A., D'Angelo C., Jansen B., Gleave M.E., and Zupi G. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. J. Cell. Physiol. 204 (2005) 463-469
63. Blanchard F., and Chipoy C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?. Drug Discov. Today 10 (2005) 197-204